This report is being filed on an international product, list number 04j27-84 (architect hiv ag/ab combo) that has a similar product distributed in the us, list number(b)(4).An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.
|
The complaint investigation for false nonreactive architect hiv ag/ab combo result included a review of data and information provided by the customer, search for similar complaints, ticket trending review, device history record review, and labeling review.In-house testing of retained reagent kit was also completed.Return testing was not performed as returns were not available.Data and information provided by the customer were reviewed and support the complaint issue.Ticket search by lot indicates that the reagent lot performs as expected for this product.Trending review did not identify any trends for the issue for the product.Device history record review did not identify any non-conformances or deviations with the likely cause lot number and complaint issue.Labeling was reviewed and found to be adequate.In-house testing of a retained reagent kit of the lot 56082be00 was performed.All specifications were met, and no false nonreactive results were obtained, showing that the lot generates the expected results.In addition, the clinical sensitivity was evaluated by testing two commercially available seroconversion panels (zeptometrix hiv 9013 and hiv 9016).The seroconversion panel results were compared to architect hiv test results provided by zeptometrix and the reagent lot detected the same bleeds as reactive.Based on these data, it was shown that the sensitivity performance of the lot is not adversely affected.Based on our investigation, no systemic issue or deficiency with the architect hiv ag/ab combo reagent for lot 56082be00 was identified.The following sections have been corrected to reflect the current contact (b)(6).
|